Healthcare | Monday 27 March, 2017 10:52 am |

Last October, the Chinese government approved a blueprint called “Healthy China 2030”, pledging to build a healthy China in the next 15 years. By 2030, the size of the healthcare market is expected to reach $2.3 trillion. This initiative is in line with China’s determination to deepen the supply-side structural reforms in 2017 by substantially driving down overcapacity, and increasing efficient supply which call for stricter standards in healthcare industry. The next 15 years will see a surge of investment and changes in the industry.

Healthcare China 2017, organized by Reed Sinopharm Exhibitions (RSE), is a platform for global investors to discover more about the dynamics of healthcare business in China. To be held on May 13-14, 2017, at the Pullman Shanghai, the event will attract corporate leaders, government regulators, influencers, researchers and entrepreneurs, focusing on three main areas of investors’ interest—biomedical, medical devices, and medical services.

SURGING POTENTIAL

China’s healthcare market is projected to grow at an unprecedented CAGR of about 12% to reach $1 trillion by 2020, up from $357 billion in 2011, as estimated in a recent report from McKinsey & Co. Against the backdrop of key technological changes such as artificial intelligence, Healthcare China 2017 will invite the principal of IBM Watson to deliver a speech on “The Future of Artificial Intelligence in Medical Industry”. Besides, industrial experts will discuss market trends and analyse government programs aiming to promote a tiered healthcare system, ensure effective drug delivery and management.

PROMOTING INTERNATIONAL PARTNERSHIP

China’s healthcare sector has been attracting increasing investment from global investors who are keen on entering or expanding their presence in China. Healthcare China 2017, which features the Top 60 innovative healthcare companies in China today, and profiles at least 500 influential CEOs and partners of leading investment companies, will be a place for global healthcare companies to demonstrate their product and process excellence, and learn China’s regulations and policies in the industry.